Highlights
Interim results from the phase 4 EPI-MAL-003 study provide robust evidence of the real-world effectiveness of the RTS,S/AS01E vaccine. Key findings include:
- A 58% reduction in the incidence of severe malaria among vaccinated children compared to unvaccinated cohorts.
- A 36% reduction in malaria-related hospitalizations and a 21% decrease in all-cause hospitalizations, indicating a significant reduction in health system burden.
- A 19% reduction in the odds of anemia among hospitalized children, highlighting the vaccine’s impact on secondary morbidity.
- Consistent effectiveness across diverse epidemiological settings in Ghana, Kenya, and Malawi during the first year of follow-up after the primary three-dose series.
